Search

Your search keyword '"Chenevix-Trench, G."' showing total 1,518 results

Search Constraints

Start Over You searched for: Author "Chenevix-Trench, G." Remove constraint Author: "Chenevix-Trench, G."
1,518 results on '"Chenevix-Trench, G."'

Search Results

151. Shared heritability and functional enrichment across six solid cancers

152. Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer

153. Polygenic risk scores for prediction of breast cancer and breast cancer subtypes

154. Publisher Correction: Shared heritability and functional enrichment across six solid cancers (Nature Communications, (2019), 10, 1, (431), 10.1038/s41467-018-08054-4)

155. Risk factors for symptomatic venous thromboembolism during therapy for childhood acute lymphoblastic leukemia.

157. DNA mismatch repair gene MSH6 implicated in determining age at natural menopause

158. The BRCA2 c.68-7T > A variant is not pathogenic: A model for clinical calibration of spliceogenicity

159. Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation (vol 5, 4999, 2014)

160. Adult height is associated with increased risk of ovarian cancer: A Mendelian randomisation study

161. Bromodomain protein 4 discriminates tissue-specific super-enhancers containing disease-specific susceptibility loci in prostate and breast cancer

162. The BRCA2 c.68‐7T > A variant is not pathogenic:a model for clinical calibration of spliceogenicity

163. Risk factors for symptomatic venous thromboembolism during therapy for childhood acute lymphoblastic leukemia

164. Abstract P5-10-01: Using whole genome sequencing and somatic mutation signatures to unravel insight into familial breast cancer aetiology

166. Assessment of moderate coffee consumption and risk of epithelial ovarian cancer: a Mendelian randomization study

167. rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology

168. Heritable DNA methylation marks associated with susceptibility to breast cancer /631/67/69 /631/337/176/1988 /692/699/67/1347 /692/308/2056 /45 /45/61 article.

169. Genome-wide association study of paclitaxel and carboplatin disposition in women with epithelial ovarian cancer

170. The BRCA2 c.68-7T > A variant is not pathogenic: A model for clinical calibration of spliceogenicity

171. Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma.

172. Adult height is associated with increased risk of ovarian cancer: A Mendelian randomisation study

173. The BRCA2 c.68-7T > A variant is not pathogenic: A model for clinical calibration of spliceogenicity

174. Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma

175. Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations

176. MyD88 and TLR4 Expression in Epithelial Ovarian Cancer

177. rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology

178. Publisher Correction: Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation.

179. A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer

180. The BRCA2 c.68‐7T > A variant is not pathogenic:a model for clinical calibration of spliceogenicity

181. Genome-wide association study of paclitaxel and carboplatin disposition in women with epithelial ovarian cancer

182. More on Co-Occurrence of COMT and BRCA1/2 Variants in a Population

183. Analyses of germline variants associated with ovarian cancer survival identify functional candidates at the 1q22 and 19p12 outcome loci

184. Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores

185. Bromodomain protein 4 discriminates tissue-specific super-enhancers containing disease-specific susceptibility loci in prostate and breast cancer

186. Evaluation of copy-number variants as modifiers of breast and ovarian cancer risk for BRCA1 pathogenic variant carriers

187. No evidence that genetic variation in the myeloid-derived suppressor cell pathway influences ovarian cancer survival

188. Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers

189. Evaluation of polygenic risk scores for breast and ovarian cancer risk prediction in BRCA1 and BRCA2 mutation carriers

190. Body mass index and breast cancer survival: a Mendelian randomization analysis

191. Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers

192. Body mass index and breast cancer survival:a Mendelian randomization analysis

193. Genetic variation in mitotic regulatory pathway genes is associated with breast tumor grade

194. Risk of Ovarian Cancer and the NF-? B Pathway: Genetic Association with IL1A and TNFSF10

196. MyD88 and TLR4 Expression in Epithelial Ovarian Cancer

197. Abstract PD1-15: The landscape of somatic genetic alterations in breast cancers from ATM germline mutation carriers

198. Traceback: A Proposed Framework to Increase Identification and Genetic Counseling of BRCA1 and BRCA2 Mutation Carriers Through Family-Based Outreach

199. Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes

200. RAD51B in familial breast cancer.

Catalog

Books, media, physical & digital resources